Filgrastim (Indonesian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Filgrastim" in Indonesian language version.

refsWebsite

Global rank Indonesian rank

1^st place

2^nd place

4^th place

4^th place

13^th place

447^th place

792^nd place

195^th place

203^rd place

low place

dddmag.com (Global: low place; Indonesian: low place)

"FDA Reviews What Could Be First Biosimilar". Discov. Dev. Mag. Rockaway, New Jersey, United States. Associated Press. 25 July 2014. Diarsipkan dari asli tanggal 2014-07-29. Diakses tanggal 2016-09-22.

Beveridge, R. A.; Miller, J. A.; Kales, A. N.; Binder, R. A.; Robert, N. J.; Harvey, J. H.; Windsor, K.; Gore, I.; Cantrell, J. (1998). "A Comparison of Efficacy of Sargramostim (Yeast-Derived RhuGM-CSF) and Filgrastim (Bacteria-Derived RhuG-CSF) in the Therapeutic Setting of Chemotherapy-Induced Myelosuppression". Cancer Investigation. 16 (6): 366–373. doi:10.3109/07357909809115775. PMID 9679526.
Crawford, J.; Glaspy, J. A.; Stoller, R. G.; Tomita, D. K.; Vincent, M. E.; McGuire, B. W.; Ozer, H. (2005). "Final Results of a Placebo-Controlled Study of Filgrastim in Small-Cell Lung Cancer: Exploration of Risk Factors for Febrile Neutropenia". Supportive Cancer Therapy. 3 (1): 36–46. doi:10.3816/SCT.2005.n.023. PMID 18632435.

"FDA approves first biosimilar product Zarxio", FDA, March 6, 2015, diarsipkan dari asli tanggal 2018-01-26, diakses tanggal 23 November 2015

Beveridge, R. A.; Miller, J. A.; Kales, A. N.; Binder, R. A.; Robert, N. J.; Harvey, J. H.; Windsor, K.; Gore, I.; Cantrell, J. (1998). "A Comparison of Efficacy of Sargramostim (Yeast-Derived RhuGM-CSF) and Filgrastim (Bacteria-Derived RhuG-CSF) in the Therapeutic Setting of Chemotherapy-Induced Myelosuppression". Cancer Investigation. 16 (6): 366–373. doi:10.3109/07357909809115775. PMID 9679526.
Crawford, J.; Glaspy, J. A.; Stoller, R. G.; Tomita, D. K.; Vincent, M. E.; McGuire, B. W.; Ozer, H. (2005). "Final Results of a Placebo-Controlled Study of Filgrastim in Small-Cell Lung Cancer: Exploration of Risk Factors for Febrile Neutropenia". Supportive Cancer Therapy. 3 (1): 36–46. doi:10.3816/SCT.2005.n.023. PMID 18632435.

"FDA approves first biosimilar product Zarxio", FDA, March 6, 2015, diarsipkan dari asli tanggal 2018-01-26, diakses tanggal 23 November 2015
"19th WHO Model List of Essential Medicines (April 2015)" (PDF). WHO. April 2015. Diarsipkan dari asli (PDF) tanggal 2015-05-13. Diakses tanggal May 10, 2015.
"FDA Reviews What Could Be First Biosimilar". Discov. Dev. Mag. Rockaway, New Jersey, United States. Associated Press. 25 July 2014. Diarsipkan dari asli tanggal 2014-07-29. Diakses tanggal 2016-09-22.

"19th WHO Model List of Essential Medicines (April 2015)" (PDF). WHO. April 2015. Diarsipkan dari asli (PDF) tanggal 2015-05-13. Diakses tanggal May 10, 2015.